Literature DB >> 17825017

Bayesian inference for the lead time in periodic cancer screening.

Dongfeng Wu1, Gary L Rosner, Lyle D Broemeling.   

Abstract

This article develops a probability distribution for the lead time in periodic cancer screening examinations. The general aim is to allow statistical inference for a screening program's lead time, the length of time the diagnosis is advanced by screening. The program's lead time is distributed as a mixture of a point mass and a piecewise continuous distribution. Simulation studies using the HIP (Health Insurance Plan for Greater New York) study's data provide estimates of different characteristics of a screening program under different screening frequencies. The components of this mixture represent two aspects of screening's benefit, namely, a reduction in the number of interval cases and the extent by which screening advanced the age of diagnosis. We present estimates of these two measures for participants in a breast cancer screening program. We also provide the mean, mode, variance, and density curve of the program's lead time. The model can provide policy makers with important information regarding the screening period, frequency, and the endpoints that may serve as surrogates for the benefit to women who take part in a periodic screening program. Though the study focuses on breast cancer screening, it is also applicable to other kinds of chronic disease.

Entities:  

Mesh:

Year:  2007        PMID: 17825017      PMCID: PMC2020448          DOI: 10.1111/j.1541-0420.2006.00732.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  12 in total

1.  Estimation of post-lead-time survival under dependence between lead-time and post-lead-time survival.

Authors:  J L Xu; R M Fagerstrom; P C Prorok
Journal:  Stat Med       Date:  1999-01-30       Impact factor: 2.373

2.  Alternative definitions of comparable case groups and estimates of lead time and benefit time in randomized cancer screening trials.

Authors:  Karen Kafadar; Philip C Prorok
Journal:  Stat Med       Date:  2003-01-15       Impact factor: 2.373

3.  Estimating benefits of screening from observational cohort studies.

Authors:  W D Flanders; I M Longini
Journal:  Stat Med       Date:  1990-08       Impact factor: 2.373

4.  MLE and Bayesian inference of age-dependent sensitivity and transition probability in periodic screening.

Authors:  Dongfeng Wu; Gary L Rosner; Lyle Broemeling
Journal:  Biometrics       Date:  2005-12       Impact factor: 2.571

5.  Estimating lead time and sensitivity in a screening program without estimating the incidence in the screened group.

Authors:  H Straatman; P G Peer; A L Verbeek
Journal:  Biometrics       Date:  1997-03       Impact factor: 2.571

6.  Non-parametric estimation of the post-lead-time survival distribution of screen-detected cancer cases.

Authors:  J L Xu; P C Prorok
Journal:  Stat Med       Date:  1995-12-30       Impact factor: 2.373

7.  Estimation of the duration of a pre-clinical disease state using screening data.

Authors:  S D Walter; N E Day
Journal:  Am J Epidemiol       Date:  1983-12       Impact factor: 4.897

8.  Use of the hazard rate to schedule follow-up exams efficiently. An optimization approach to patient management.

Authors:  A J Dwyer; J M Prewitt; J G Ecker; J Plunkett
Journal:  Med Decis Making       Date:  1983       Impact factor: 2.583

9.  A data-analytic approach for estimating lead time and screening benefit based on survival curves in randomized cancer screening trials.

Authors:  K Kafadar; P C Prorok
Journal:  Stat Med       Date:  1994 Mar 15-Apr 15       Impact factor: 2.373

10.  Using observational data to estimate an upper bound on the reduction in cancer mortality due to periodic screening.

Authors:  Stuart G Baker; Diane Erwin; Barnett S Kramer; Philip C Prorok
Journal:  BMC Med Res Methodol       Date:  2003-03-06       Impact factor: 4.615

View more
  10 in total

1.  Sojourn time and lead time projection in lung cancer screening.

Authors:  Dongfeng Wu; Diane Erwin; Gary L Rosner
Journal:  Lung Cancer       Date:  2010-11-13       Impact factor: 5.705

2.  Estimating key parameters in periodic breast cancer screening-application to the Canadian National Breast Screening Study data.

Authors:  Yinlu Chen; Guy Brock; Dongfeng Wu
Journal:  Cancer Epidemiol       Date:  2010-08       Impact factor: 2.984

3.  How does early detection by screening affect disease progression? Modeling estimated benefits in prostate cancer screening.

Authors:  Elisabeth M Wever; Gerrit Draisma; Eveline A M Heijnsdijk; Harry J de Koning
Journal:  Med Decis Making       Date:  2011-03-15       Impact factor: 2.583

4.  Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis.

Authors:  Yusuke Yamamoto; Hisashi Ikoma; Ryo Morimura; Katsutoshi Shoda; Hirotaka Konishi; Yasutoshi Murayama; Shuhei Komatsu; Atsushi Shiozaki; Yoshiaki Kuriu; Takeshi Kubota; Masayoshi Nakanishi; Daisuke Ichikawa; Hitoshi Fujiwara; Kazuma Okamoto; Chouhei Sakakura; Toshiya Ochiai; Eigo Otsuji
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

5.  Estimation of Lead Time via Low-Dose CT in the National Lung Screening Trial.

Authors:  Ruiqi Liu; Adriana Pérez; Dongfeng Wu
Journal:  J Healthc Inform Res       Date:  2018-06-12

6.  When to initiate cancer screening exam?

Authors:  Dongfeng Wu
Journal:  Stat Interface       Date:  2022-03-04       Impact factor: 0.716

7.  A projection of benefits due to fecal occult blood test for colorectal cancer.

Authors:  Dongfeng Wu; Diane Erwin; Gary L Rosner
Journal:  Cancer Epidemiol       Date:  2009-09-04       Impact factor: 2.984

8.  Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement.

Authors:  Peter J Mazzone; Catherine Rufatto Sears; Doug A Arenberg; Mina Gaga; Michael K Gould; Pierre P Massion; Vish S Nair; Charles A Powell; Gerard A Silvestri; Anil Vachani; Renda Soylemez Wiener
Journal:  Am J Respir Crit Care Med       Date:  2017-10-01       Impact factor: 21.405

9.  Inferences for the Lead Time in Breast Cancer Screening Trials under a Stable Disease Model.

Authors:  Justin Shows; Dongfeng Wu
Journal:  Cancers (Basel)       Date:  2011-04-26       Impact factor: 6.639

10.  Bayesian lead time estimation for the Johns Hopkins Lung Project data.

Authors:  Hyejeong Jang; Seongho Kim; Dongfeng Wu
Journal:  J Epidemiol Glob Health       Date:  2013-06-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.